Sionna Therapeutics, Inc.
SION
Positions held
Your positionsSION isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $221.24M | Enterprise value | $18.58M | Trailing P/E | — | Forward P/E | -2.20 |
| PEG | — | Price / book | 0.83 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -32.3% | ROA | -21.5% | Debt / equity | 0.03 |
| Current ratio | 20.05 | Free cash flow | -$45.44M | Analyst recommendation | hold | Mean target | $21.00 |
| 52w high | $54.97 | 52w low | $4.01 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$29.9M | -$26.8M | -$20.4M | -$20.3M | -$18.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$32.5M | -$29.6M | -$23.6M | -$23.8M | -$21.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$75.3M | -$61.7M | -$47.3M | -$40.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$89.0M | -$70.6M | -$50.3M | -$41.4M |
Headlines — watch
• [WARN · fundamentals] Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
News
2026-10-08 · Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
2026-09-17 · Sionna Therapeutics (SION) Approves 46% Job Cut. Can a New Trial Make its Cash More Productive?
2026-09-16 · SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
2026-09-15 · FDA clears first generic radioligand drug; Sionna turns to layoffs
2026-09-15 · Wedbush Raises Price Target on Sionna Therapeutics to $6 From $5, Keeps Neutral Rating
2026-08-20 · Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
2026-08-13 · Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep?
2026-08-12 · Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says
2026-08-12 · Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall
2026-08-12 · One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses
Price (daily)
Full chart · RSI · MACD · patterns